Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other ...
Secures agreement pausing conversion rights until January 2027 (unless closing share price equals or exceeds $0.275) and ...
(“NEXGEL” or the “Company”) (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team ...
Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 ...
Vincora (NeoChord, Inc. d/b/a Vincora), a medical technology company developing transcatheter therapies for mitral valve ...
(Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the ...
In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in ...
Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife ...
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing ...
The corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry’s biggest spender.
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results